Bristol-Myers Squibb Co.

NYSE:BMY   3:59:59 PM EDT
67.29
-0.05 (-0.07%)
4:33:59 PM EDT: $67.42 +0.13 (+0.19%)
Products, Regulatory

U.S. Food And Drug Administration Approves Bristol Myers Squibb’S Zeposia® (Ozanimod), An Oral Treatment For Adults With Moderately To Severely Active Ulcerative Colitis1

Published: 05/27/2021 21:52 GMT
Bristol-Myers Squibb Co. (BMY) - U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Zeposia® (ozanimod), an Oral Treatment for Adults With Moderately to Severely Active Ulcerative Colitis1.
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Zeposia® (ozanimod), an Oral Treatment for Adults With Moderately to Severely Active Ulcerative Colitis1.